| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Mineralys Therapeutics Inc. | Lorundrostat | Chronic Kidney Disease | Phase 2 | Ongoing | Oral | N/A |
| Mineralys Therapeutics Inc. | Lorundrostat - (ADVANCE-HTN) | Uncontrolled hypertension (uHTN) and resistant hypertension (rHTN) | Phase 2 | Data Released | oral | Cardiology |
| Mineralys Therapeutics Inc. | Lorundrostat - (Target-HTN) | Hypertension | Phase 2 | Data Released | Oral | Cardiology |
| Minerva Neurosciences Inc | Seltorexant - (MIN-202) | Primary insomnia | Phase 2b | Trial Completed | Oral | Psychiatric |
| Minerva Neurosciences Inc | MIN-117 | Major Depressive Disorder | Phase 2b | Trial Discontinued | Oral | Psychiatric |
| Minerva Neurosciences Inc | Seltorexant (MIN-202) | Major Depressive Disorder | Phase 2 | Trial Completed | Oral | Psychiatric |
| MiNK Therapeutics Inc. | AgenT-797 | Refractory (2L+) gastric cancer, refractory gastroesophageal cancer (GEC) | Phase 2 | Data Released | Intravenous | Oncology |
| MiNK Therapeutics Inc. | Botensilimab plus balstilimab, agenT-797 | Gastric cancer | Phase 2 | Enrollment Initiation | Intravenous | Oncology |